Annovis Bio Inc Ordinary Shares ANVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANVS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $8.99
- Day Range
- $9.04–9.88
- 52-Week Range
- $5.42–22.49
- Bid/Ask
- $10.00 / $10.20
- Market Cap
- $108.46 Mil
- Volume/Avg
- 241,573 / 214,377
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.annovisbio.com
Comparables
Valuation
|
Metric
|
ANVS
|
EWTX
|
IMVT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.67 | 6.05 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANVS
|
EWTX
|
IMVT
|
|---|---|---|---|
Quick Ratio | 1.34 | 18.98 | 21.56 |
Current Ratio | 2.39 | 19.50 | 22.14 |
Interest Coverage | — | — | — |
Quick Ratio
ANVS
EWTX
IMVT
Profitability
|
Metric
|
ANVS
|
EWTX
|
IMVT
|
|---|---|---|---|
Return on Assets (Normalized) | −189.56% | −24.36% | −43.33% |
Return on Equity (Normalized) | −291.73% | −25.87% | −47.83% |
Return on Invested Capital (Normalized) | −296.63% | −29.82% | −52.69% |
Return on Assets
ANVS
EWTX
IMVT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lkywyzcwct | Xlp | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Stfbsqddp | Yqydhks | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wclkclnq | Xlxrcy | $98.1 Bil | |
MRNA
| Moderna Inc | Rmwdmgdf | Pbz | $39.7 Bil | |
ARGX
| argenx SE ADR | Lyrhjbrc | Ctxky | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Kcfbzzdcp | Gwn | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sswtkds | Qdvvzc | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ysddzybn | Yxzrrt | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bzjlqbxwt | Twrjfw | $12.5 Bil | |
INCY
| Incyte Corp | Kplxrsl | Fmpvnh | $11.8 Bil |